The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lonsdorf, A. S.
Right arrow Articles by Tary-Lehmann, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lonsdorf, A. S.
Right arrow Articles by Tary-Lehmann, M.
The Journal of Immunology, 2003, 171: 3941-3946.
Copyright © 2003 by The American Association of Immunologists

Intratumor CpG-Oligodeoxynucleotide Injection Induces Protective Antitumor T Cell Immunity 1

Anke S. Lonsdorf*,{dagger}, Haydar Kuekrek*, Britta V. Stern*, Bernhard O. Boehm{dagger}, Paul V. Lehmann* and Magdalena Tary-Lehmann2,*

* Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106; and {dagger} Section of Endocrinology, University Hospitals of Ulm, Ulm, Germany

Tumor cells are typically poorly immunogenic. The same mechanisms that evolved to avoid the induction of immune responses against self tissues, and, hence, autoimmune disease, also have to be overcome for immune therapy of cancer. Toll-like receptor-activating microbial products such as CpG motif containing DNA are among the primary stimuli that the immune system uses to distinguish between infectious nonself (that is to be attacked) and noninfectious self (that must not be attacked). We tested in a murine RMA lymphoma/C57BL/6 model whether providing the infectious nonself context in a tumor–by injecting CpG-oligodeoxynucleotides directly into the tumor–would elicit a protective antitumor response. Complete remission of established solid tumors was achieved in immune competent mice, but not in T cell/B cell-deficient RAG-1 knockout mice. Intratumor injection of CpG-oligodeoxynucleotides was shown to induce a tumor-specific CD4+ and CD8+ T cell response of the type 1 effector class, and T cells adoptively transferred the protection to RAG-1 knockout mice. The data show that intratumor injection of CpG-oligodeoxynucleotides is a promising strategy for rendering tumors immunogenic.




This article has been cited by other articles:


Home page
 J. Gen. Virol.Home page
H. Yu, H. Huang, J. Xiang, L. A. Babiuk, and S. van Drunen Littel-van den Hurk
Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3
J. Gen. Virol., January 1, 2006; 87(1): 1 - 10.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
O. Preynat-Seauve, P. Schuler, E. Contassot, F. Beermann, B. Huard, and L. E. French
Tumor-Infiltrating Dendritic Cells Are Potent Antigen-Presenting Cells Able to Activate T Cells and Mediate Tumor Rejection
J. Immunol., January 1, 2006; 176(1): 61 - 67.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
I. N. Buhtoiarov, H. D. Lum, G. Berke, P. M. Sondel, and A. L. Rakhmilevich
Synergistic Activation of Macrophages via CD40 and TLR9 Results in T Cell Independent Antitumor Effects
J. Immunol., January 1, 2006; 176(1): 309 - 318.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
J. M. Kim, N. I. Kim, Y.-K. Oh, Y.-J. Kim, J. Youn, and M.-J. Ahn
CpG oligodeoxynucleotides induce IL-8 expression in CD34+ cells via mitogen-activated protein kinase-dependent and NF-{kappa}B-independent pathways
Int. Immunol., December 1, 2005; 17(12): 1525 - 1531.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
K. McKenna, A.-S. Beignon, and N. Bhardwaj
Plasmacytoid Dendritic Cells: Linking Innate and Adaptive Immunity
J. Virol., January 1, 2005; 79(1): 17 - 27.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. A. Mason, H. Ariga, R. Neal, D. Valdecanas, N. Hunter, A. M. Krieg, J. K. Whisnant, and L. Milas
Targeting Toll-like Receptor 9 with CpG Oligodeoxynucleotides Enhances Tumor Response to Fractionated Radiotherapy
Clin. Cancer Res., January 1, 2005; 11(1): 361 - 369.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Wysocka, B. M. Benoit, S. Newton, L. Azzoni, L. J. Montaner, and A. H. Rook
Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15
Blood, December 15, 2004; 104(13): 4142 - 4149.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. J. D. van Mierlo, Z. F. H. M. Boonman, H. M. H. Dumortier, A. Th. den Boer, M. F. Fransen, J. Nouta, E. I. H. van der Voort, R. Offringa, R. E. M. Toes, and C. J. M. Melief
Activation of Dendritic Cells That Cross-Present Tumor-Derived Antigen Licenses CD8+ CTL to Cause Tumor Eradication
J. Immunol., December 1, 2004; 173(11): 6753 - 6759.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. Li, Z. Ma, Z.-L. Tang, T. Stevens, B. Pitt, and S. Li
CpG DNA-mediated immune response in pulmonary endothelial cells
Am J Physiol Lung Cell Mol Physiol, September 1, 2004; 287(3): L552 - L558.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. J. Kemp, J. M. Moore, and T. S. Griffith
Human B Cells Express Functional TRAIL/Apo-2 Ligand after CpG-Containing Oligodeoxynucleotide Stimulation
J. Immunol., July 15, 2004; 173(2): 892 - 899.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2003 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2003 by The American Association of Immunologists, Inc. All rights reserved.